Tell your doctor before starting to take this medicine if you: are pregnant, trying to get pregnant or breastfeeding
Thankfully, it’s not very 2
Results Final result of phase 3 study in 1433 non-hospitalized COVID-19 patients showed a significant reduction in composite risk of hospital admission or death
MOVe-OUT is an ongoing, phase 2/3, randomized, placebo-controlled, double-blind study evaluating the safety, efficacy, and pharmacokinetics of molnupiravir in nonhospitalized adults
Headaches Diarrhoea Feeling or being sick (nausea or vomiting) Serious side effects There are no known serious side effects with molnupiravir
Based on in vitro studies, neither molnupiravir nor its active metabolite
Molnupiravir is potentially teratogenic and is
University of Illinois Chicago